. 2019 Jul 18;19:499. doi: 10.1186/s12913-019-4303-y

Table 2.

Cost-effectiveness, Reference-case

Strategy	Mean Costs, $	Mean Effects, QALMs	Incremental Costs, $	Incremental Effects, QALMs	ICER^†, $/QALM gained
Community pharmacist-initiated	72.47 (49.74; 99.61)	0.75137 (0.50954; 0.92395)	–	–	–
Family physician-initiated	141.53 (96.11; 198.26)	0.75142 (0.50910; 0.92384)	69.06 (16.16; 129.67)	0.00005 (−0.00673; 0.00718)	1,381,200
Emergency physician-initiated	368.16 (227.21; 543.26)	0.75146 (0.51983; 0.92400)	–	–	Extended dominance

Strategy

Mean Costs, $

Mean Effects, QALMs

Incremental Costs, $

Incremental Effects, QALMs

ICER^†,
$/QALM gained

Community pharmacist-initiated

72.47

(49.74; 99.61)

0.75137

(0.50954; 0.92395)

–

Family physician-initiated

141.53

(96.11; 198.26)

0.75142

(0.50910; 0.92384)

69.06

(16.16; 129.67)

0.00005

(−0.00673; 0.00718)

1,381,200

Emergency physician-initiated

368.16

(227.21; 543.26)

0.75146

(0.51983; 0.92400)

–

Extended dominance

^†Sequential analysis